Negotiations database

Indication:

in combination with carboplatin and paclitaxel by public drug plans for the first-line treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).

Indication:

For the treatment of patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation

Indication:

Multiple Indications

Indication:

Multiple Indications

Indication:

Giant Cell Arteritis

Indication:

For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy.

Indication:

Testosterone replacement therapy

Indication:

For the treatment of adult patients with Cushing's disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and/or irradiation, or for whom pituitary surgery is not an option.

Indication:

Zepzelca, in combination with atezolizumab, for the first-line maintenance treatment of extensive-stage small cell lung cancer in adult patients whose disease has not progressed following induction therapy with atezolizumab, carboplatin and etoposide

Indication:

For the treatment of adults with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens